MN-EVOLVE-ADDITIVE-SOLUT
8.9.2021 17:02:04 CEST | Business Wire | Press release
Today Evolve Additive Solutions (“EAS”) announces that 3D Ventures and its affiliates have agreed to a $30 million growth equity financing in the company. EAS will use these funds to accelerate commercial sales of its SVP (scaled volume production) platform in the U.S., Europe, and Canada. This fundraising follows a period of growth in which Evolve has meaningfully expanded its product portfolio over the past 6 months.
The investment comes in the form of an SPV (special purpose vehicle), with closing is expected in the third quarter of 2021. Proceeds will be used to accelerate the commercial deployments of the company’s high throughput 3D printer.
3D Ventures and its affiliates are seasoned operators and investors with decades of experience in the 3D printing, additive manufacturing and related industries. The principals are Hugh Evans, Joe Allison and Wally Loewenbaum. They bring a unique pedigree of industry talents, expertise and resources to the company in addition to investment capital.
Joe Allison, Managing Partner of 3D Ventures, stated, “I have printed many parts over the course of my career, and in my opinion the Evolve SVP system is the best 3D printer capable of competing directly with injection molding in terms of part quality, part cost and throughput.”
In 2018 Evolve received $25 million in investment capital from Stanley Black and Decker, The LEGO Group and Stratasys. 3D Ventures broadens Evolve’s portfolio of partners to include both strategic and financial groups.
“Funding from 3D Ventures reflects their confidence in our business model, our growth trajectory and our ability to meet a need in the additive manufacturing marketplace,” stated, Steve Chillscyzn, CEO and Founder of Evolve. “We are now balanced with excellent backing in place from both the strategic and investment partners.” He added: “This investment presents a major step forward in fueling our growth and better positioning ourselves as a manufacturing solutions organization.”
Evolve’s STEP (selective thermoplastic electrophotographic process) technology sits alongside traditional manufacturing processes, such as injection molding, on the manufacturing floor and augments an organization’s production capabilities allowing freedom of design and faster time to market with “toolless” production.
About Evolve Additive Solutions
Evolve Additive Solutions is transforming how the world manufactures. Founded in 2017, the company offers Additive Manufacturing production equipment, materials, software, service, consulting and application services. Evolve allows for manufacturing flexibility, creating uniquely functional products while increasing speed to market and efficiency securing supply chains. Evolve’s patented STEP (selective thermoplastic electrophotographic process) technology is able to efficiently produce commercial grade production parts and create unique products that cannot be manufactured with traditional methods. The company is headquartered in Minnetonka, MN with a materials technology center based in Rochester, NY.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release
Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release
New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release
The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom